You may already know a lot of the names that are considered leaders of the diabetes technology industry. The likes of Abbott and Dexcom are leaders in the continuous glucose monitor (CGM) space. MiniMed, Insulet and Tandem Diabetes Care are a few of the companies with a significant share in the automated insulin delivery (AID) […]
Sequel Med Tech
Sequel Med Tech chief medical officer explains why company is ‘excited about what’s ahead’
Sequel Med Tech has a habit of making waves at the American Diabetes Association’s annual Scientific Sessions event. In 2024, the Manchester, New Hampshire-based company was generating buzz following its entry into the automated insulin delivery market with twiist, its pump system, which had garnered FDA clearance in March of that year. At last year’s […]
Sequel Med Tech data supports twiist automated insulin delivery in type 2 diabetes
Sequel Med Tech today announced clinical findings supporting its twiist automated insulin delivery (AID) system in type 2 diabetes. twiist, which works with the twiist Loop algorithm, powered by Tidepool, directly measures the volume of insulin delivered with every microdose. The system offers the capability and flexibility to address each patient’s individual dosing needs. Sequel’s system […]
Sequel fully launches twiist automated insulin pump in US, looks to expand access for type 1 diabetes
Sequel Med Tech today announced the broad availability of its twiist automated insulin delivery system in the U.S. The company plans to expand access to automated insulin delivery for people with type 1 diabetes through a wider rollout of the pump, making it fully available nationwide. Manchester, New Hampshire–based Sequel built its twiist system to […]
Sequel, Senseonics announce full launch of Eversense 365 CGM, twiist pump pairing
Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. Manchester, New Hampshire-based Sequel and Germantown, Maryland-based Senseonics now offer the Eversense 365 continuous glucose monitor (CGM) with the twiist automated insulin delivery (AID) system for people with type 1 diabetes in the U.S. The companies […]
Sequel Med Tech, Diabeloop to integrate automated insulin delivery algorithm into twiist pump
Sequel Med Tech and Diabeloop today announced a collaboration to integrate a new algorithm into the twiist automated insulin pump. The partnership aims to bring DBLG2, Diabeloop’s newest automated insulin delivery (AID) algorithm, to twiist. DBLG2 picked up FDA clearance last month. Sequel becomes the latest pump maker to adopt the algorithm, with ViCentra planning to […]
Senseonics launches Eversense 365 CGM with Sequel twiist pump
Senseonics (NYSE:SENS) announced today that it began the launch of its Eversense 365 sensor with the Sequel Med Tech twiist pump. The companies said today that the first commercial patients have now received their paired continuous glucose monitor (CGM) and automated insulin delivery (AID) system. They announced their intent to integrate technologies in April 2025. […]
The top diabetes tech stories of 2025
As the year comes to a close, it’s time to look back at the numerous innovations across the diabetes technology industry in 2025. Once again, continuous glucose monitors (CGMs) and automated insulin delivery systems took most of the headlines, as the leaders in the space keep building on their platforms while challengers continue to enter […]
What diabetes tech companies are doing on World Diabetes Day 2025
Once again, World Diabetes Day, celebrated on Nov. 14 every year, has come around, highlighting new initiatives in the diabetes tech space. The date marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National Diabetes Awareness Month. […]
Sequel Med Tech, Arecor ink co-development agreement for ultra-rapid insulin with twiist
Arecor Therapeutics announced today that it signed a co-development with Sequel Med Tech to pair their diabetes offerings. Cambridge, UK-based Arecor develops AT278 (500U/mL) ultra-rapid-acting insulin. The companies struck a deal to pair the insulin with the Sequel twiist automated insulin delivery system. Additionally, the deal includes a financing agreement with Ligand Pharmaceuticals to bring […]
